The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed its initial recommendation to not consider deutetrabenazine as a new active substance. In June this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback